Biocept Company Profile (NASDAQ:BIOC)

About Biocept (NASDAQ:BIOC)

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic & Testing Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BIOC
  • CUSIP: N/A
  • Web: www.biocept.com
Capitalization:
  • Market Cap: $37.82 million
  • Outstanding Shares: 30,253,000
Average Prices:
  • 50 Day Moving Avg: $1.28
  • 200 Day Moving Avg: $1.56
  • 52 Week Range: $0.74 - $3.39
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.89
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.3 million
  • Price / Sales: 7.14
  • Book Value: $0.26 per share
  • Price / Book: 4.81
Profitability:
  • EBIDTA: ($18,190,000.00)
  • Net Margins: -359.48%
  • Return on Equity: -550.35%
  • Return on Assets: -175.51%
Debt:
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 2.13%
  • Quick Ratio: 2.02%
Misc:
  • Average Volume: 328,072 shs.
  • Beta: 3.02
  • Short Ratio: 14.97
 

Frequently Asked Questions for Biocept (NASDAQ:BIOC)

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The company earned $1.28 million during the quarter, compared to analyst estimates of $1.23 million. Biocept had a negative net margin of 359.48% and a negative return on equity of 550.35%. View Biocept's Earnings History.

When will Biocept make its next earnings announcement?

Biocept is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Biocept.

Where is Biocept's stock going? Where will Biocept's stock price be in 2017?

3 brokers have issued 1-year price objectives for Biocept's shares. Their predictions range from $2.00 to $3.00. On average, they anticipate Biocept's share price to reach $2.50 in the next year. View Analyst Ratings for Biocept.

Who are some of Biocept's key competitors?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:

  • Michael W. Nall, President, Chief Executive Officer, Director
  • Timothy C. Kennedy, Chief Financial Officer and Senior Vice President of Operations
  • Lyle J. Arnold Ph. D., Senior Vice President - Research & Development, Chief Scientific Officer
  • Veena Singh M.D., Senior Vice President, Senior Medical Director
  • Michael Terry, Senior Vice President - Commercial Operations
  • Raaj Trivedi, Vice President - Commercial Operations
  • David S. Moskowitz, Vice President - Strategy and Corporate Communications
  • David F. Hale, Non-Executive Chairman of the Board
  • Marsha A. Chandler Ph.D., Independent Director
  • Bruce E. Gerhardt CPA, Independent Director

Who owns Biocept stock?

Biocept's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ALLY BRIDGE LB HEALTHCARE MASTER FUND LTD (14.46%), Vanguard Group Inc. (2.87%) and Creative Planning (0.93%). Company insiders that own Biocept stock include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Institutional Ownership Trends for Biocept.

Who bought Biocept stock? Who is buying Biocept stock?

Biocept's stock was acquired by a variety of institutional investors in the last quarter, including Creative Planning and Vanguard Group Inc.. Company insiders that have bought Biocept stock in the last two years include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Insider Buying and Selling for Biocept.

How do I buy Biocept stock?

Shares of Biocept can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of Biocept stock can currently be purchased for approximately $1.25.


MarketBeat Community Rating for Biocept (NASDAQ BIOC)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biocept (NASDAQ:BIOC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (100.00% upside)

Analysts' Ratings History for Biocept (NASDAQ:BIOC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Westpark CapitalReiterated RatingOutperformLowView Rating Details
3/13/2017Roth CapitalReiterated RatingBuy$1.60 -> $3.00LowView Rating Details
11/10/2016Feltl & Co.UpgradeHold -> Buy$2.00N/AView Rating Details
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50N/AView Rating Details
1/10/2016HC WainwrightReiterated RatingBuy$4.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Biocept (NASDAQ:BIOC)
Earnings by Quarter for Biocept (NASDAQ:BIOC)
Earnings History by Quarter for Biocept (NASDAQ BIOC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017N/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.21)$1.23 million$1.28 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.34)($0.27)$1.26 million$1.29 millionViewListenView Earnings Details
11/9/2016Q316($0.57)($0.57)$0.76 million$1.05 millionViewListenView Earnings Details
8/2/2016Q216($0.22)($0.20)$0.37 million$0.66 millionViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)$0.48 million$0.22 millionViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$0.78 million$0.17 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)$0.30 million$0.15 millionViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)$0.30 million$0.08 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.82)($0.87)$0.40 million$0.01 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.67)($0.67)$0.10 million$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biocept (NASDAQ:BIOC)
2017 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.19)($0.21)
Q2 20172($0.21)($0.19)($0.20)
Q3 20172($0.21)($0.17)($0.19)
Q4 20172($0.20)($0.18)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biocept (NASDAQ:BIOC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biocept (NASDAQ:BIOC)
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 6.92%
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)
Institutional Ownership by Quarter for Biocept (NASDAQ:BIOC)
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2016Claire ReissMajor ShareholderBuy227,272$1.10$249,999.20View SEC Filing  
10/19/2016David F. HaleDirectorBuy90,909$1.10$99,999.90View SEC Filing  
10/19/2016Lyle J. ArnoldSVPBuy45,000$1.10$49,500.00View SEC Filing  
10/19/2016Timothy KennedyCFOBuy36,363$1.10$39,999.30View SEC Filing  
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biocept (NASDAQ:BIOC)
Latest Headlines for Biocept (NASDAQ:BIOC)
Source:
DateHeadline
nasdaq.com logo5 Medtech Stocks to Steer Clear of Amid Political Chaos - Nasdaq
www.nasdaq.com - September 20 at 2:33 AM
finance.yahoo.com logo5 Medtech Stocks to Steer Clear of Amid Political Chaos
finance.yahoo.com - September 19 at 4:31 PM
americanbankingnews.com logoBiocept, Inc. (BIOC) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 17 at 2:50 AM
americanbankingnews.com logo Analysts Anticipate Biocept, Inc. (BIOC) Will Announce Quarterly Sales of $1.40 Million
www.americanbankingnews.com - September 9 at 8:22 AM
finance.yahoo.com logoBiocept Launches Liquid Biopsy Test for NRAS Mutations
finance.yahoo.com - September 5 at 6:10 PM
americanbankingnews.com logoBiocept, Inc. (BIOC) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - September 3 at 9:00 PM
finance.yahoo.com logoBiocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
finance.yahoo.com - August 28 at 4:33 PM
finance.yahoo.com logoBiocept to Present at the 6th Annual Gateway Conference on September 6, 2017 in San Francisco
finance.yahoo.com - August 28 at 4:33 PM
americanbankingnews.com logoBiocept, Inc. (BIOC) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 23 at 3:32 AM
americanbankingnews.com logoBiocept, Inc. (BIOC) Expected to Post Quarterly Sales of $1.40 Million
www.americanbankingnews.com - August 21 at 5:06 AM
reuters.com logoBRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock
www.reuters.com - August 18 at 9:38 PM
prnewswire.com logoBiocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung ... - PR Newswire (press release)
www.prnewswire.com - August 17 at 10:57 PM
reuters.com logoBRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients
www.reuters.com - August 17 at 5:55 PM
finance.yahoo.com logoBiocept and UT Southwestern Medical Center Announce Clinical Study to Profile and Monitor Non-Small Cell Lung Cancer Patients with ALK Rearrangements
finance.yahoo.com - August 17 at 5:55 PM
americanbankingnews.com logoZacks Investment Research Downgrades Biocept, Inc. (BIOC) to Sell
www.americanbankingnews.com - August 16 at 5:04 PM
reuters.com logoBRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR
www.reuters.com - August 14 at 9:59 PM
reuters.com logoBRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR - Reuters
www.reuters.com - August 14 at 4:57 PM
finance.yahoo.com logoBiocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR
finance.yahoo.com - August 14 at 4:57 PM
americanbankingnews.com logoBiocept, Inc. (BIOC) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 6:02 PM
seekingalpha.com logoBiocept's (BIOC) CEO Michael Nall on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 3:48 AM
finance.yahoo.com logoBiocept Announces Private Placement of $2.2 Million of Common Stock with Ally Bridge LB Healthcare Master Fund
finance.yahoo.com - August 10 at 5:41 PM
finance.yahoo.com logoBiocept Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 5:41 PM
reuters.com logoBRIEF-Biocept executes preferred provider agreement with Scripps Health Plan
www.reuters.com - August 8 at 9:24 PM
nasdaq.com logoHealth Care Sector Update for 08/07/2017: BIOC - Nasdaq
www.nasdaq.com - August 7 at 10:05 PM
finance.yahoo.com logoBiocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform
finance.yahoo.com - August 7 at 5:04 PM
americanbankingnews.com logoCritical Analysis: Biocept (BIOC) & Natera (NTRA)
www.americanbankingnews.com - August 4 at 7:42 AM
finance.yahoo.com logoETFs with exposure to Biocept, Inc. : August 3, 2017
finance.yahoo.com - August 3 at 11:03 PM
americanbankingnews.com logoComparing TrovaGene (TROV) and Biocept (NASDAQ:BIOC)
www.americanbankingnews.com - August 3 at 8:48 PM
americanbankingnews.com logoBiocept, Inc. (NASDAQ:BIOC) to Release Earnings on Thursday
www.americanbankingnews.com - August 3 at 8:10 PM
prnewswire.com logoBiocept to Release Second Quarter 2017 Financial Results and ... - PR Newswire (press release)
www.prnewswire.com - August 3 at 6:00 PM
finance.yahoo.com logoBiocept to Release Second Quarter 2017 Financial Results and Host Investor Conference Call on August 10, 2017
finance.yahoo.com - August 3 at 6:00 PM
americanbankingnews.com logoAnalyzing Biocept (NASDAQ:BIOC) & NanoString Technologies (NSTG)
www.americanbankingnews.com - August 1 at 10:26 PM
americanbankingnews.com logoBiocept (BIOC) vs. TrovaGene (TROV) Head to Head Survey
www.americanbankingnews.com - July 30 at 6:25 PM
americanbankingnews.com logoBiocept, Inc. (NASDAQ:BIOC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 29 at 7:27 AM
finance.yahoo.com logoGlobal stocks rise on corporate earnings, ahead of Fed
finance.yahoo.com - July 26 at 5:08 PM
americanbankingnews.com logoBiocept, Inc. (NASDAQ:BIOC) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 24 at 8:04 AM
americanbankingnews.com logoReviewing Biocept (NASDAQ:BIOC) and NanoString Technologies (NSTG)
www.americanbankingnews.com - July 20 at 6:27 PM
americanbankingnews.com logoFinancial Contrast: NanoString Technologies (NSTG) and Biocept (BIOC)
www.americanbankingnews.com - July 19 at 4:12 PM
finance.yahoo.com logoFeatured Company News - Biocept Commercially Launches Progesterone Receptor Liquid Biopsy Test
finance.yahoo.com - July 17 at 4:51 PM
americanbankingnews.com logoFinancial Analysis: Biocept (BIOC) versus Quotient Limited (QTNT)
www.americanbankingnews.com - July 16 at 10:28 PM
prnewswire.com logoBiocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for ... - PR Newswire (press release)
www.prnewswire.com - July 14 at 11:33 PM
nasdaq.com logoETF Preview: ETFs, Stocks Point to Higher Open as Wall Street Mulls Earnings from Banks, Retail Sales and Inflation Data
www.nasdaq.com - July 14 at 6:29 PM
reuters.com logoBRIEF-Biocept launches liquid biopsy test for progesterone receptor detection
www.reuters.com - July 14 at 6:29 PM
finance.yahoo.com logoBiocept Expands Commercial Offering of Clinically Actionable Biomarker Assays with Launch of Liquid Biopsy Test for Progesterone Receptor Detection
finance.yahoo.com - July 14 at 6:29 PM
bizjournals.com logoGlobal Circulating Tumor Cell (CTC) Diagnostics - Biotechnology
www.bizjournals.com - July 13 at 1:42 AM
finance.yahoo.com logoETFs with exposure to Biocept, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:05 PM
finance.yahoo.com logoFDA advisers endorse what could be 1st US gene therapy
finance.yahoo.com - July 12 at 5:05 PM
americanbankingnews.com logoZacks Investment Research Downgrades Biocept, Inc. (BIOC) to Hold
www.americanbankingnews.com - July 12 at 4:46 PM
americanbankingnews.com logoBiocept, Inc. (BIOC) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - July 9 at 12:02 AM
americanbankingnews.com logoBiocept, Inc. (BIOC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 4 at 10:02 AM

Social

Chart

Biocept (BIOC) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff